Given the results of KEYNOTE-062 presented at ASCO 2019, how will you utilize immunotherapy in gastric cancer?

Interpretation of Keynote-062 study results is complicated. The primary endpoint was non-inferiority of pembrolizumab alone versus chemotherapy for first line therapy in patients with CPS>1. This primary endpoint was met, however the PFS curves are quite revealing in that chemotherapy arm does much ...